Search research articles
Contact Us
Filters
Showing results (121-130 of 201) with videos related to
Page
of 21
Sort By:
Oncotarget
|
January 27, 2018
Cell-surface marker discovery for lung cancer
Allison S Cohen, Farah K Khalil, Eric A Welsh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 25, 2010
A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer
Eric B Haura, Alejandro D Ricart, Timothy G Larson, et al.
Molecular Cancer Therapeutics
|
September 25, 2023
MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling
Nan Chen, Logan C Tyler, Anh T Le, et al.
The Journal of Clinical Investigation
|
May 3, 2013
Lung tumor NF-κB signaling promotes T cell-mediated immune surveillance
Emily L Hopewell, Weipeng Zhao, William J Fulp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 2017
MET-GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors
Matthew A Smith, Thomas Licata, Aliya Lakhani, et al.
Science Signaling
|
November 5, 2016
Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors
Guolin Zhang, Hannah Scarborough, Jihye Kim, et al.
Proteomics
|
February 15, 2017
Relative protein quantification and accessible biology in lung tumor proteomes from four LC-MS/MS discovery platforms
Paul A Stewart, Bin Fang, Robbert J C Slebos, et al.
Cancer Immunology, Immunotherapy : CII
|
December 29, 2018
Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer
Alberto A Chiappori, Charles C Williams, Jhanelle E Gray, et al.
Contemporary Clinical Trials
|
July 30, 2016
Smoking relapse-prevention intervention for cancer patients: Study design and baseline data from the surviving SmokeFree randomized controlled trial
Diana B Díaz, Thomas H Brandon, Steven K Sutton, et al.
Cancer Research
|
August 1, 2019
MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer
Mengyu Xie, Hong Zheng, Ranjna Madan-Lala, et al.
Page
of 21
Search research articles
Search
Showing results (121-130 of 201) with videos related to
Sort By:
Page
of 21
Oncotarget
|
January 27, 2018
Cell-surface marker discovery for lung cancer
Allison S Cohen, Farah K Khalil, Eric A Welsh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 25, 2010
A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer
Eric B Haura, Alejandro D Ricart, Timothy G Larson, et al.
Molecular Cancer Therapeutics
|
September 25, 2023
MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling
Nan Chen, Logan C Tyler, Anh T Le, et al.
The Journal of Clinical Investigation
|
May 3, 2013
Lung tumor NF-κB signaling promotes T cell-mediated immune surveillance
Emily L Hopewell, Weipeng Zhao, William J Fulp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 2017
MET-GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors
Matthew A Smith, Thomas Licata, Aliya Lakhani, et al.
Science Signaling
|
November 5, 2016
Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors
Guolin Zhang, Hannah Scarborough, Jihye Kim, et al.
Proteomics
|
February 15, 2017
Relative protein quantification and accessible biology in lung tumor proteomes from four LC-MS/MS discovery platforms
Paul A Stewart, Bin Fang, Robbert J C Slebos, et al.
Cancer Immunology, Immunotherapy : CII
|
December 29, 2018
Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer
Alberto A Chiappori, Charles C Williams, Jhanelle E Gray, et al.
Contemporary Clinical Trials
|
July 30, 2016
Smoking relapse-prevention intervention for cancer patients: Study design and baseline data from the surviving SmokeFree randomized controlled trial
Diana B Díaz, Thomas H Brandon, Steven K Sutton, et al.
Cancer Research
|
August 1, 2019
MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer
Mengyu Xie, Hong Zheng, Ranjna Madan-Lala, et al.
Page
of 21